Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.

person Alicia Frances Clare Okines The Royal Marsden NHS Foundation Trust, London, United Kingdom info_outline Alicia Frances Clare Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive, Hatem Hussein Soliman, Shunji Takahashi, Tanios S. Bekaii-Saab, Erika P. Hamilton, Bradley J. Monk, Yoshiaki Nakamura, Danny Nguyen, David M. O'Malley, Martin Reck, Evan Y. Yu, Jorge Ramos, Sherry Tan, Tom Stinchcombe, Paula R Pohlmann

Authors person Alicia Frances Clare Okines The Royal Marsden NHS Foundation Trust, London, United Kingdom info_outline Alicia Frances Clare Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive, Hatem Hussein Soliman, Shunji Takahashi, Tanios S. Bekaii-Saab, Erika P. Hamilton, Bradley J. Monk, Yoshiaki Nakamura, Danny Nguyen, David M. O'Malley, Martin Reck, Evan Y. Yu, Jorge Ramos, Sherry Tan, Tom Stinchcombe, Paula R Pohlmann Organizations The Royal Marsden NHS Foundation Trust, London, United Kingdom, Istituto Europeo di Oncologia, Milan, IRCCS and University of Milano, Milan, Italy, Aichi Cancer Center Hospital, Nagoya, Japan, Seoul National University Hospital, Seoul, South Korea, CHU de Liege, Liege, Belgium, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Mayo Clinic Scottsdale, Scottsdale, AZ, Sarah Cannon Research Institute, Nashville, TN, Florida Cancer Specialists and Research Institute, West Palm Beach, FL, National Cancer Center Hospital East, Kashiwa, Japan, City of Hope National Medical Center, Duarte, CA, The Ohio State University and James Comprehensive Cancer Center, Columbus, OH, Department of Thoracic Oncology, Airway Research Center North, Germany Center for Lung Disease, Grosshansdorf, Grosshansdorf, Germany, Fred Hutchinson Cancer Center/University of Washington, Seattle, WA, Pfizer Inc., Bothell, WA, Duke Cancer Institute, Durham, NC, The University of Texas MD Anderson Cancer Center, Houston, TX Abstract Disclosures Research Funding This study was sponsored by Seagen, which was acquired by Pfizer in Dec. 2023. Background: Approximately 2-5% of breast cancers harbor HER2 mutations, often occurring in hormone receptor-positive (HR+) disease. There are currently no approved treatment options for patients (pts) with HER2-mutated metastatic breast cancer (HER2-mut MBC). Tucatinib (TUC) is a tyrosine kinase inhibitor highly selective for HER2 and is approved for previously treated HER2+ MBC with or without brain metastases in combination with trastuzumab (Tras) and capecitabine. Here, we report the efficacy and safety results of TUC combined with Tras in pts with previously treated HER2-mut MBC. Methods: SGNTUC-019 (NCT04579380) is an open-label phase 2 basket study evaluating efficacy, safety, and tolerability of TUC and Tras in pts with metastatic HER2-altered solid tumors. Pts in the HER2-mut MBC cohort must have HER2 mutations determined locally by tissue- or blood-based next-generation sequencing, not be HER2+ per local testing, been previously treated with ≥1 systemic therapy in the locally advanced, unresectable, or metastatic setting, and if HR+, have received a CDK4/6 inhibitor. Pts were treated in 21-day cycles with TUC (300 mg orally twice a day) and Tras (8 mg/kg IV followed by 6 mg/kg every 3 wks). Pts with HR+ disease also received fulvestrant (F; 500 mg IM once every 4 wks starting from cycle 1 day 1, and cycle 1 day 15). Disease status was determined based on RECIST v1.1 with assessments performed every 6 wks for 24 wks and every 12 wks thereafter. The primary endpoint is cORR per investigator assessment. Secondary endpoints include OS, DCR, DOR, PFS, and safety. Results: As of Nov 1, 2023, 31 pts were enrolled in the HER2-mut MBC cohort. The median duration of follow-up for OS was 15.0 months. Twenty-seven (87%) pts had HR+ disease and 18 (58%) had lobular histology. The pts received a median of 4 prior lines of systemic therapy in any setting. cORR was 41.9% (90% CI, 26.9-58.2) with 13 responses including 2 complete responses. Median DOR was 12.6 months (90% CI, 4.7, not estimable), DCR was 80.6% (n=25; 90% CI, 65.3-91.2), median PFS was 9.5 months (90% CI, 5.4-13.8), and median OS was 20.1 months (90% CI, 15.9 to not estimable). The most common treatment-emergent adverse events (TEAEs) reported were diarrhea (64.5%) and nausea (35.5%). The most common grade ≥3 TEAEs reported were diarrhea (13%), alanine aminotransferase increase (10%), and hypertension (10%). Two (6.5%) pts discontinued TUC due to TEAEs, but these pts continued Tras. No deaths were due to TEAEs. Additional biomarker analyses will be included in the presentation. Conclusions: The investigational combination of TUC and Tras, plus F in pts with HR+ disease, was well tolerated and had clinical activity in pts with previously treated HER2-mut MBC. The results support further evaluation of the combination of TUC and Tras as a potential treatment option for this pt population. Clinical trial information: NCT04579380.

Clinical